Clinical trials: Intravenous Immunoglobulin
Influenza
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR6261, a monoclonal antibody against influenza A viruses.
- Trial name
- NCT01406418
- Testing
- CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
CIDP, Immunoglobulin Deficiency
IVIG vs SCIG in CIDP
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in…
- Conditions
- CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy
- Trial name
- NCT05584631
- Testing
- Intravenous immune globulin G, Subcutaneous immune globulin G
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rutgers, The State University of New Jersey
Primary Immunodeficiency Diseases (PID)
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID).
- Trial name
- NCT06565078
- Testing
- Immune Globulin Subcutaneous (Human), 20% Solution
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Takeda
Motor Neuron Disease
LIME Study (LFB IVIg MMN Efficacy Study)
The aim of this study is to evaluate the efficacy and safety of I10E (LFB 10% ready-to-use liquid human intravenous immunoglobulin) compared to Kiovig® for the maintenance treatment of MMN in a randomized, double-blind, active…
- Trial name
- LIME (NCT01951924)
- Testing
- Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL), Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
- Where
- 18 sites in France, Italy and 2 more
- Volunteers
- 23 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Immune-Mediated Necrotizing Myopathy
Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)
This is a phase 2, pilot, randomized, placebo-controlled trial of Gamunex-C IVIG as mono-therapy for HMGCoA reductase auto-antibody positive (HMGCR) necrotizing myopathy.
- Trial name
- NCT04450654
- Testing
- Gamunex-C, Albumin
- Where
- United States
- Sponsor
- University of Washington
ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement. Performed by the European Vasculitis Study group.
- Conditions
- ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- NCT00430105
- Testing
- cyclophosphamide
- Volunteers
- 160 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Spinocerebellar Degenerations
High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
This study will examine whether high-dose intravenous immunoglobulin (IVIG) is safe and effective for treating cerebellar ataxia-degeneration of the cerebellum, the part of the brain responsible for coordinating muscle movements…
- Trial name
- NCT00034242
- Testing
- high-dose intravenous immunoglobulin (IVIG)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
The objective of this study is to develop a rationale for the selective treatment of small fiber neuropathy with immune globulin (IVIG) in the appropriate patients.
- Trial name
- NCT03401073
- Testing
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center